StevenJayIsakoffMDPhD

Oncology • Boston, MA

Breast Cancer

Assistant Professor in Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Isakoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Isakoff's full profile

Already have an account?

Office
55 Fruit St
Yawkey 9A
Boston, MA 02114
Phone+1 617-726-6500

Fax+1 617-643-0589

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2002
New York University School of MedicineClass of 2000, MD, PhD
Princeton UniversityAB, Molecular Biology, Cum Laude, 1987 - 1991

Certifications & Licensure

MA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response Start of enrollment: 2007 Jun 01
Completed
Phase 2
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer Start of enrollment: 2008 Aug 01
Completed
Not Applicable
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 2
Trastuzumab and Vinorelbine in Advanced Breast Cancer Start of enrollment: 2010 Nov 01
Terminated
Phase 2
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 1
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa Start of enrollment: 2012 Oct 01
Active, not recruiting
Phase 2
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01
Completed
Phase 2
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 1
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer Start of enrollment: 2016 Oct 01
Unknown status
Phase 2
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Start of enrollment: 2017 Dec 12
Active, not recruiting
Phase 1
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy Start of enrollment: 2019 Feb 01
Active, not recruiting
Not Applicable
Onvansertib + Paclitaxel In TNBC Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer Start of enrollment: 2021 Jul 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Laura M Spring, Lauren Scarpetti, Arielle J Medford, Andrzej Niemierko, Amy Comander
NPJ Breast Cancer. 2025-01-07
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-01-02
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.
Bogang Wu, Win Thant, Elena Bitman, Ting Liu, Jie Liu
Biorxiv. 2024-12-05

Press Mentions

When to Get First Mammogram? Doctor Explains Latest AdviceMay 12th, 2023
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-Negative, BRCA-Mutated Breast CancerAugust 10th, 2022
Ribociclib Dose Modifications Do Not Affect OS in Patients with Hr+/her2 Advanced Breast CancerJune 21st, 2022
Join now to see all